Role of interleukin-32 in Helicobacter pylori-induced gastric inflammation

Infection and Immunity

Volumn 80, Issue 11, 2012, Pages 3795-3803

  Sakitani, Kosuke ^a   Hirata, Yoshihiro ^a   Hayakawa, Yoku ^a   Serizawa, Takako ^b   Nakata, Wachiko ^a   Takahashi, Ryota ^a   Kinoshita, Hiroto ^a   Sakamoto, Kei ^b   Nakagawa, Hayato ^a   Akanuma, Masao ^b   Yoshida, Haruhiko ^a   Maeda, Shin ^c   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b INSTITUTE FOR ADULT DISEASES   (Japan)

^c YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 32; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CAGPAI GENE; CONTROLLED STUDY; DISEASE SEVERITY; EPITHELIUM CELL; GASTRITIS; GENE; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CANCER; STOMACH MUCOSA; UPREGULATION;

CELL LINE; CLONING, ORGANISM; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTERLEUKINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84867605419     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00637-12     Document Type: Article

References (54)

1. Aihara M, et al. 1997. Mechanisms involved in Helicobacter pyloriinduced interleukin-8 production by a gastric cancer cell line, MKN45. Infect. Immun. 65:3218-3224.
2. Backert S, Naumann M. 2010. What a disorder: proinflammatory signaling pathways induced by Helicobacter pylori. Trends Microbiol. 18:479-486.
3. Bai XY, et al. 2010. IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages. J. Immunol. 184:3830-3840.
4. Choi JD, et al. 2009. Identification of the most active interleukin-32 isoform. Immunology 126:535-542.
5. Correa P. 1992. Human gastric carcinogenesis-a multistep and multifactorial process. 1st American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 52:6735-6740.
6. Crabtree JE, et al. 1995. Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with cagA positive phenotype. J. Clin. Pathol. 48:41-45.
7. Dahl CA, Schall RP, He HL, Cairns JS. 1992. Identification of a novel gene expressed in activated natural killer cells and T cells. J. Immunol. 148:597-603.
8. de Vries AC, et al. 2008. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 134:945-952.
9. El-Omar EM, et al. 2000. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398-402.
10. Fukase K, et al. 2008. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372:392-397.
11. Glocker E, et al. 1998. Proteins encoded by the cag pathogenicity island of Helicobacter pylori are required for NF-kappa B activation. Infect. Immun. 66:2346-2348.
12. Goda C, et al. 2006. Involvement of IL-32 in activation-induced cell death in T cells. Int. Immunol. 18:233-240.
13. Hasegawa H, Thomas HJ, Schooley K, Born TL. 2011. Native IL-32 is released from intestinal epithelial cells via a non-classical secretory pathway as a membrane-associated protein. Cytokine 53:74-83.
14. Heinhuis B, et al. 2011. Inflammation-dependent secretion and splicing of IL-32 gamma in rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A. 108:4962-4967.
15. Hirata Y, et al. 2001. Helicobacter pylori activates the cyclin D1 gene through mitogen-activated protein kinase pathway in gastric cancer cells. Infect. Immun. 69:3965-3971.
16. Hirata Y, et al. 2002. Helicobacter pylori CagA protein activates serum response element-driven transcription independently of tyrosine phosphorylation. Gastroenterology 123:1962-1971.
17. Hirata Y, et al. 2006. Helicobacter pylori induces I kappa B kinase at nuclear translocation and chemokine production in gastric epithelial cells. Infect. Immun. 74:1452-1461.
18. Hong SN, et al. 2012. Clinical characteristics and the expression profiles of inflammatory cytokines/cytokine regulatory factors in asymptomatic patients with nodular gastritis. Dig. Dis. Sci. 6:1486-1495.
19. Karin M, Lawrence T, Nizet V. 2006. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124:823-835.
20. Karin M, Lin A. 2002. NF-kappa B at the crossroads of life and death. Nat. Immunol. 3:221-227.
21. Kato A, et al. 2010. IL-32 expression in chronic rhinosinusitis. J. Allergy Clin. Immunol. 125:AB61.
22. Kim KH, et al. 2008. Interleukin-32 monoclonal antibodies for immunohistochemistry, Western blotting, and ELISA. J. Immunol. Methods 333:38-50.
23. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. 2005. Interleukin32: a cytokine and inducer of TNF alpha. Immunity 22:131-142.
24. Ko NY, et al. 2011. Interleukin-32 alpha production is regulated by MyD88-dependent and independent pathways in IL-1 beta-stimulated human alveolar epithelial cells. Immunobiology 216:32-40.
25. Kobayashi H, et al. 2010. Interleukin-32 beta propagates vascular inflammation and exacerbates sepsis in a mouse model. PLoS One 5:e9458. doi: 10.1371/journal.pone.0009458.
26. Kobayashi H, Lin PC. 2009. Molecular characterization of IL-32 in human endothelial cells. Cytokine 46:351-358.
27. Luheshi NM, Rothwell NJ, Brough D. 2009. Dual functionality of interleukin-1 family cytokines: implications for anti-interleukin-1 therapy. Br. J. Pharmacol. 157:1318-1329.
28. Maeda S, et al. 2001. Distinct mechanism of Helicobacter pylorimediated NF-kappa B activation between gastric cancer cells and monocytic cells. J. Biol. Chem. 276:44856-44864.
29. Maeda S, Mentis AF. 2007. Pathogenesis of Helicobacter pylori infection. Helicobacter 12:10-14.
30. Maeda S, et al. 2000. H. pylori activates NF-kappa B through a signaling pathway involving I kappa B kinases, NF-kappa B-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells. Gastroenterology 119:97-108.
31. Mitsuno Y, et al. 2001. Helicobacter pylori induced transactivation of SRE and AP-1 through the ERK signalling pathway in gastric cancer cells. Gut 49:18-22.
32. Moschen AR, et al. 2011. Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. Hepatology 53:1819-1829.
33. Mun SH, et al. 2009. Tumor necrosis factor alpha-induced interleukin-32 is positively regulated via the Syk/protein kinase C delta/JNK pathway in rheumatoid synovial fibroblasts. Arthritis Rheum. 60:678-685.
34. Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH. 2003. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann. Pharmacother. 37:1256-1265.
35. Netea MG, et al. 2006. Mycobacterium tuberculosis induces interleukin-32 production through a caspase1/IL-18/interferon-gammadependent mechanism. PLoS Med. 3:1310-1319.
36. Nishida A, Andoh A, Inatomi O, Fujiyama Y. 2009. Interleukin-32 expression in the pancreas. J. Biol. Chem. 284:17868-17876.
37. Nold-Petry CA, et al. 2009. IL-32-dependent effects of IL-1 beta on endothelial cell functions. Proc. Natl. Acad. Sci. U. S. A. 106:3883-3888.
38. Ogura K, et al. 2008. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J. Clin. Gastroenterol. 42:279-283.
39. Ogura K, et al. 1998. Interleukin-8 production in primary cultures of human gastric epithelial cells induced by Helicobacter pylori. Dig. Dis. Sci. 43:2738-2743.
40. Ohmae T, et al. 2005. Helicobacter pylori activates NF-kappa B via the alternative pathway in B lymphocytes. J. Immunol. 175:7162-7169.
41. Pan XF, et al. 2011. Interleukin-32 expression induced by hepatitis B virus protein X is mediated through activation of NF-kappa B. Mol. Immunol. 48:1573-1577.
42. Sakitani K, et al. 2011. Gastric cancer risk according to the distribution of intestinal metaplasia and neutrophil infiltration. J. Gastroenterol. Hepatol. 26:1570-1575.
43. Segal ED, Cha J, Lo J, Falkow S, Tompkins LS. 1999. Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc. Natl. Acad. Sci. U. S. A. 96:14559-14564.
44. Shioya M, et al. 2007. Epithelial overexpression of interleukin-32 alpha in inflammatory bowel disease. Clin. Exp. Immunol. 149:480-486.
45. Shoda H, et al. 2006. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res. Ther. 8:R166.
46. Sorrentino C, Di Carlo E. 2009. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am. J. Respir. Crit. Care Med. 180:769-779.
47. Sugimoto M, et al. 2007. Different effects of polymorphisms of tumor necrosis factor-alpha and interleukin-1 beta on development of peptic ulcer and gastric cancer. J. Gastroenterol. Hepatol. 22:51-59.
48. Sugimoto M, Ohno T, Graham DY, Yamaoka Y. 2011. Helicobacter pylori outer membrane proteins on gastric mucosal interleukin 6 and 11 expression in Mongolian gerbils. J. Gastroenterol. Hepatol. 26: 1677-1684.
49. Suzuki M, et al. 1997. Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication. J. Clin. Gastroenterol. 25:S222-S228.
50. Taguchi A, et al. 2005. Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol. Biomarkers Prev. 14:2487-2493.
51. Uemura N, et al. 2001. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345:784-789.
52. Warren JR, Marshall BJ. 1983. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet i:1273.
53. Wong BCY, et al. 2004. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China-a randomized controlled trial. JAMA 291:187-194.
54. Yagi Y, et al. 2011. Interleukin-32 alpha expression in human colonic subepithelial myofibroblasts. Int. J. Mol. Med. 27:263-268.